Biofrontera price to sales ratio BFRI

Market value divided by revenue over the last twelve months, since 2022.

Today, Oct 23, 2026: 0.3×
4-year median: 0.3×
Against its 4-year history: 47th; percentile: 0 is its lowest day, 100 its highest
4-year range: 0.0× to 1.2×
Peer median: 0.9×

Biofrontera's price to sales ratio is 0.3× as of Oct 23, 2026.

That is below its 4-year median of 0.3×, close to the middle of its last 4 years.

Over that time it ranged from 0.0× in Feb 2024 to 1.2× in Aug 2022.

The median for 3 large drugmakers of a similar size is 0.9×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	0.3×	0.2×	0.5×
2025	0.2×	0.1×	0.3×
2024	0.2×	0.0×	0.3×
2023	0.1×	0.1×	1.0×
2022	0.9×	0.8×	1.2×

Against its peers

Companies in Drug Manufacturers - General nearest Biofrontera's size, closest first, today.

Company	Price to sales ratio
BFRIBiofrontera	0.3×
ATNMActinium Pharmaceuticals	n/m
SPROSpero Therapeutics	1.4×
LFVNLifevantage	0.4×
Peer median	0.9×

Where Biofrontera ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Biofrontera

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.